[Clinical efficacy and safety of Zo-20 in patients with ischemic heart disease].
Since their introduction in the late 1980s, the 3- hydroxy-3 -methilglutaryl coenzyme A (HMG -CoA) reductaze inhibitors or statins, have revolutionized the treatment of hyperlipidemia. Despite the well-recognized benefits of statins, there is evidence that low density lipoprotein cholesterol (LDL-C) reductions as specified by National Cholesterol Education Program (NCEP) are not being met. The aim of the study was to assess the efficacy of Zo-20 ("GMP", Georgia) in achieving the target level for LDL-C in patients with CAD and hypercholesterinemia. 100 patients received 20-40 mg Zo-20 during the 3 months period, all parameters of the blood plasma lipids and adverse events were monitored during the study. 78% of patients reached the target goal for LDL-C, using 28,2 mg Zo-20 daily. No serious adverse events associated with study drug treatment were revealed. Zo-20 seems to be very effective and safety in treatment of patients with CAD and lipid disorders.
Mamatsashvili
M
M
Angio-cardiac Clinic Adapt, Tbilisi, Georgia.
Mdivani
I
I
D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000453:epidemiology*; D011446:Prospective Studies; D019821:Simvastatin / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019821:Simvastatin